{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:43Z","timestamp":1792372123574,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41409-019-0469-5","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T17:03:59Z","timestamp":1549299839000},"page":"1471-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3623","authenticated-orcid":false,"given":"Hidehiro","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-0620","authenticated-orcid":false,"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Iwato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoko","family":"Takanashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJMra0902908","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872\u201385.","journal-title":"N Engl J Med"},{"key":"469_CR2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"469_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"469_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","volume":"110","author":"C Chang","year":"2007","unstructured":"Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110:1379\u201387.","journal-title":"Blood"},{"key":"469_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ajh.20989","volume":"82","author":"CM Flynn","year":"2007","unstructured":"Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol. 2007;82:867\u201372.","journal-title":"Am J Hematol"},{"key":"469_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2016.266","volume":"52","author":"M Robin","year":"2017","unstructured":"Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transpl. 2017;52:209\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"469_CR7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V88.1.358.358","volume":"88","author":"L Sutton","year":"1996","unstructured":"Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle. Blood. 1996;88:358\u201365.","journal-title":"Blood"},{"key":"469_CR8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","volume":"92","author":"TJ Nevill","year":"1998","unstructured":"Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910\u20137.","journal-title":"Blood"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","volume":"120","author":"HJ Deeg","year":"2012","unstructured":"Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120:1398\u2013408.","journal-title":"Blood"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.leukres.2014.07.009","volume":"38","author":"M D\u00edez Campelo","year":"2014","unstructured":"D\u00edez Campelo M, S\u00e1nchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, et al. Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients. Leuk Res. 2014;38:1199\u2013206.","journal-title":"Leuk Res"},{"key":"469_CR11","unstructured":"Shaffer L, Tommerup NE. An international System for Human Cytogenetic Nomenclature (2005). Basel: Karger; 2005."},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/sj.leu.2404619","volume":"21","author":"M Sanada","year":"2007","unstructured":"Sanada M, Uike N, Ohyashiki K, Ozawa K, Lili W, Hangaishi A, et al. Unbalanced translocation der(1;7)(q10; p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia. 2007;21:992\u20137.","journal-title":"Leukemia"},{"key":"469_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cancergencyto.2009.04.013","volume":"193","author":"ML Slovak","year":"2009","unstructured":"Slovak ML, O\u2019Donnell M, Smith DD, Gaal K. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical\/pathologic features compared to -7\/del(7q) MDS. Cancer Genet Cytogenet. 2009;193:78\u201385.","journal-title":"Cancer Genet Cytogenet"},{"key":"469_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cancergencyto.2005.09.003","volume":"165","author":"HH Hsiao","year":"2006","unstructured":"Hsiao HH, Sashida G, Ito Y, Kodama A, Fukutake K, Ohyashiki JH. et al. Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10; p10). Cancer Genet Cytogenet. 2006;165:161\u20136.","journal-title":"Cancer Genet Cytogenet"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ajh.23230","volume":"87","author":"FT Hussain","year":"2012","unstructured":"Hussain FT, Nguyen EP, Raza S, Knudson R, Pardanani A, Hanson CA, et al. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Am J Hematol. 2012;87:684\u20136.","journal-title":"Am J Hematol"},{"key":"469_CR16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"469_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"469_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11\u201319.","journal-title":"Int J Hematol"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03006932","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269\u201374.","journal-title":"Int J Hematol"},{"key":"469_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189\u201399.","journal-title":"Br J Haematol"},{"key":"469_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"469_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Bone Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Bone Marrow Transpl"},{"key":"469_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","volume":"113","author":"Y Atsuta","year":"2009","unstructured":"Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113:1631\u20138.","journal-title":"Blood"},{"key":"469_CR24","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","volume":"101","author":"Y Inamoto","year":"2016","unstructured":"Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016;101:1592\u2013602.","journal-title":"Haematologica"},{"key":"469_CR25","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","volume":"122","author":"W Saber","year":"2013","unstructured":"Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122:1974\u201382.","journal-title":"Blood"},{"key":"469_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/bjh.13124","volume":"168","author":"K Aoki","year":"2015","unstructured":"Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T, et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. Br J Haematol. 2015;168:463\u20136.","journal-title":"Br J Haematol"},{"key":"469_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"469_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"469_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"469_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.leukres.2018.08.022","volume":"73","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sol\u00e9 F, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: analysis from the international working group for prognosis of MDS. Leuk Res. 2018;73:51\u20137.","journal-title":"Leuk Res"},{"key":"469_CR31","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/leu.2017.228","volume":"31","author":"T Zhang","year":"2017","unstructured":"Zhang T, Xu Y, Pan J, Li H, Wang Q, Wen L, et al. High frequency of RUNX1 mutation in myelodysplastic syndrome patients with whole-arm translocation of der(1;7)(q10; p10). Leukemia. 2017;31:2257\u201360.","journal-title":"Leukemia"},{"key":"469_CR32","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","volume":"30","author":"G Damaj","year":"2012","unstructured":"Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie-Cellulaire and the Groupe-Francophone des My\u00e9lodysplasies. J Clin Oncol. 2012;30:4533\u201340.","journal-title":"J Clin Oncol"},{"key":"469_CR33","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","volume":"18","author":"AT Gerds","year":"2012","unstructured":"Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"469_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bmt.2009.134","volume":"45","author":"T Field","year":"2010","unstructured":"Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:255\u201360.","journal-title":"Bone Marrow Transplant"},{"key":"469_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49:204\u201312.","journal-title":"Nat Genet"},{"key":"469_CR36","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time. Blood. 2014;124:3345\u201355.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"469_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/ijlh.12670","volume":"39","author":"NM Cruz","year":"2017","unstructured":"Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML. Minimal residual disease in acute myelogenous leukemia. Int J Lab Hem. 2017;39(Suppl. 1):53\u201360.","journal-title":"Int J Lab Hem"},{"key":"469_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-016-2706-y","volume":"95","author":"XD Mo","year":"2016","unstructured":"Mo XD, Qin YZ, Zhang XH, Xu LP, Wang Y, Yan CH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95:1233\u201340.","journal-title":"Ann Hematol"},{"key":"469_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","volume":"107","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138\u201350.","journal-title":"Int J Hematol"},{"key":"469_CR40","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/bmt.2017.31","volume":"52","author":"J El-Cheikh","year":"2017","unstructured":"El-Cheikh J, Massoud R, Fares E, Kreidieh N, Mahfouz R, Charafeddine M, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant. 2017;52:918\u201321.","journal-title":"Bone Marrow Transplant"},{"key":"469_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","volume":"22","author":"C Craddock","year":"2016","unstructured":"Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2016;22:385\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"key":"469_CR42","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M Lima de","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer . 2010;116:5420\u201331.","journal-title":"Cancer"},{"key":"469_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","volume":"8","author":"S Han","year":"2015","unstructured":"Han S, Kim YJ, Lee J, Jeon S, Hong T, Park GJ, et al. Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. J Hematol Oncol. 2015;8:118.","journal-title":"J Hematol Oncol"},{"key":"469_CR44","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bjh.13248","volume":"169","author":"G Oshikawa","year":"2015","unstructured":"Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169:756\u20139.","journal-title":"Br J Haematol"},{"key":"469_CR45","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","volume":"21","author":"I Pusic","year":"2015","unstructured":"Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transpl. 2015;21:1761\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"469_CR46","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878\u201387.","journal-title":"J Clin Oncol"},{"key":"469_CR47","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"469_CR48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00277-016-2679-x","volume":"95","author":"EJ Choi","year":"2016","unstructured":"Choi EJ, Lee JH, Lee JH, Kim DY, Park HS, Seol M, et al. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%\u2014a feasibility study. Ann Hematol. 2016;95:1151\u201361.","journal-title":"Ann Hematol"},{"key":"469_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2011.01697.x","volume":"87","author":"SE Lee","year":"2011","unstructured":"Lee SE, Kim YJ, Yahng SA, Cho BS, Eom KS, Lee S, et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol. 2011;87:510\u201320.","journal-title":"Eur J Haematol"},{"key":"469_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","volume":"104","author":"M Lima de","year":"2004","unstructured":"de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865\u201372.","journal-title":"Blood"},{"key":"469_CR51","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood-2004-02-0754","volume":"104","author":"DH Christiansen","year":"2004","unstructured":"Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104:1474\u201381.","journal-title":"Blood"},{"key":"469_CR52","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2017-12-822262","volume":"131","author":"T Inaba","year":"2018","unstructured":"Inaba T, Honda H, Matsui H. The enigma of monosomy 7. Blood. 2018;131:2891\u20138.","journal-title":"Blood"},{"key":"469_CR53","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129:2347\u201358.","journal-title":"Blood"},{"key":"469_CR54","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691\u20138.","journal-title":"J Clin Oncol"},{"issue":"30","key":"469_CR55","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","volume":"34","author":"Matteo G. Della Porta","year":"2016","unstructured":"Della Porta MG, Gall\u00ec A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34:3627\u201337.","journal-title":"Journal of Clinical Oncology"},{"key":"469_CR56","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","volume":"379","author":"EJ Duncavage","year":"2018","unstructured":"Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, et al. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379:1028\u201341.","journal-title":"N Engl J Med"},{"key":"469_CR57","first-page":"113","volume":"8","author":"U Bacher","year":"2018","unstructured":"Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood. Cancer J. 2018;8:113.","journal-title":"Cancer J"},{"key":"469_CR58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/bmt.2009.190","volume":"45","author":"JH Lee","year":"2010","unstructured":"Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transpl. 2010;45:450\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"469_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbmt.2008.11.015","volume":"15","author":"TJ Nevill","year":"2009","unstructured":"Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:205\u201313.","journal-title":"Biol Blood Marrow Transpl"},{"key":"469_CR60","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","volume":"123","author":"MG Porta Della","year":"2014","unstructured":"Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333\u201342.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0469-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:09Z","timestamp":1684617249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0469-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0469-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"1 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}